FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Vext Science, Inc. (the “Issuer”)**

Trading Symbol: **VEXT**

Number of Outstanding Listed Securities:  **44,457,891 Common Shares**

Date: **November 30, 2020**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

**General Instructions**

1. Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
2. The term “Issuer” includes the Issuer and any of its subsidiaries.
3. Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**The Issuer, through its wholly-owned subsidiaries, currently operates in the U.S. as an agricultural technology, services and property management company utilizing a full vertical integration business model to oversee and execute all aspects of cultivation, extraction, manufacturing (THC and CBD cartridges, concentrates, edibles), retail dispensary, and wholesale distribution of high margin Cannabis THC and Hemp CBD products under the Vapen Brand. VEXT SCIENCE expansion plans include partnering with cannabis license holders and hemp farms in multiple states within the U.S.**

**The Issuer was incorporated on December 11, 2015 and pursuant to a long form prospectus filed with and receipted by the British Columbia Securities Commission on May 3, 2019, it became a reporting issuer in Canada. On May 13, 2019, the Issuer was listed for trading on the Canadian Securities Exchange (the “CSE”). On June 14, 2019, the Issuer’s shares were listed on the Frankfurt Exchange under the trading symbol “VV5”**

**On July 12, 2019, the Issuer’s common shares were quoted the OTCQX® Best Market, under the symbol "VAPNF". The Issuer’s trading on the OTCQX Market comes as a result of an application and due diligence process including meeting certain financial metrics. The Issuer’s shares became DTC eligible on September 3, 2019.**

**On November 12, 2019, the Issuer changed (i) its name from Vapen MJ Ventures Corporation to Vext Science, Inc.; (ii) its ticker symbol on the U.S. OTCQX to VEXTF; and (iii) its ticker symbol on the CSE to VEXT.**

1. Provide a general overview and discussion of the activities of management.

**On November 2, 2020, the Issuer announced that it had closed its previously announced public offering of 17,777,165 units of the Company (the "Units") at a price of $0.36 per Unit for aggregate gross proceeds of approximately $6,400,000 (the "Offering"), including the partial exercise of the Agents' over-allotment option. Each Unit is comprised of one common share (each, a "Subordinated Voting Share") and one share purchase warrant (each, a "Warrant"). Each Warrant entitles the holder to purchase one Subordinated Voting Share at an exercise price of $0.45 until November 2, 2023. The Warrants commenced trading on the Canadian Securities Exchange under the symbol "VEXT.WT" on November 2, 2020.**

**The Offering was conducted on a "best efforts" basis by Beacon Securities Limited, as lead agent and sole bookrunner, on its own behalf and on behalf of a syndicate of agents including Canaccord Genuity Corp. (collectively, the "Agents").**

**As compensation, the Issuer paid to the Agents a cash fee of approximately $438,534 and issued to the Agents an aggregate of 1,218,152 share purchase warrants (the "Agents' Warrants"). Each Agents' Warrant entitles the holder thereof to purchase one Subordinated Voting Share at an exercise price of $0.36 per Subordinated Voting Share until November 2, 2023.**

**The Units were offered and sold by way of a short form prospectus filed in each of the provinces of Canada (other than Québec). The proceeds raised from the sale of Units under the Offering will be used by the Issuer for working capital and corporate expansion purposes. The final short form prospectus dated October 27, 2020 is available under the Company's profile at** [**www.sedar.com**](http://www.sedar.com)**.**

**In addition, the Issuer closed a non-brokered private placement of units, with economic terms identical to the Units, pursuant to which the Issuer issued 4,064,500 units for gross proceeds of $1,463,220 (the "Concurrent Private Placement"). Further to the Issuer’s news release dated October 7, 2020, two holders of the 10% secured non-convertible debentures of the Issuer due December 31, 2021 (the "Debentures") redeemed 20% of the principal amount of their respective Debentures (an aggregate amount of $1,463,220) and used the proceeds to participate in the Concurrent Private Placement. Accordingly, the proceeds from the Concurrent Private Placement were not new funds available to the Company; rather, the funds retired $1,463,220 of the principal amount of the Debentures. The securities issued pursuant to the Concurrent Private Placement are subject to resale restrictions, including a Canadian four-month hold period. No fees or compensation are payable to the Agents in connection with the Concurrent Private Placement.**

**On November 18, 2020, the Issuer filed an Information Circular with respect to its Annual General and Special Meeting to be held on December 10, 2020, in Vancouver, British Columbia. The Information Circular is available on SEDAR.**

**On November 24, 2020, the Issuer announced its Q3 results from operations. It was an important operational quarter for the Issuer, beginning with the successful grand opening of a second operated Phoenix dispensary, as well as the initiation of fully funded expansions across the Arizona footprint. With two operating dispensaries in the core Phoenix market and the Vapen brand in the vast majority of licensed dispensaries in the state, and active cultivation, manufacturing and kitchen facilities, the Issuer is prepared to capture anticipated growth in retail traffic in 2021. All major capital expenditures are now funded and many of the Issuer’s out-of-state expansion relationships will begin to generate results next year.**

**Subsequent to November 30, 2020, on December 1, 2020,** **Agents in the offering noted above exercised their overallotment option (the "Over-Allotment Option") in full, to purchase an additional 1,389,500 Units at a price of $0.36 per Unit for gross proceeds of approximately $500,000.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**None**

4**.** Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have beenamended or abandoned.

**None**

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship**.**

**None**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**None**

8. Describe the acquisition of new customers or loss of customers**.**

**None**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

**On November 3, 2020, residents of the State of Arizona approved Proposition 207 and thus approved the legalized possession of marijuana for adult use in the State. The Issuer has been preparing for legalization for approximately one year and is building-out retail, cultivation and manufacturing operations to ensure preparedness to handle adult use in Arizona.**

10. Report on any employee hiring, terminations, or lay-offs with details of anticipated length of layoffs.

**None**

11.Report on any labour disputes and resolutions of those disputes if applicable**.**

**None**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None**

13**.** Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None**

14. Provide details of any securities issued and options or warrants granted.

**See Item 2 above with respect to the closing of a public offering of 17,777,165 Units of the Issuer’s securities and a concurrent non-brokered private placement of 4,064,500 Units of the Issuer’s securities having identical terms as the public offering save and except for the four month holding period attached to the Units in the non-brokered private placement.**

**On November 26, 2020, the Issuer granted 375,000 stock options to certain employees and consultants of the Issuer. All of the options are exercisable at a price of CAD$0.75, are fully vested and have a 10-year term.**

15. Provide details of any loans to or by Related Persons.

**None**

16. Provide details of any changes in directors, officers, or committee members.

**None**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

**Cannabis-related Practices or Activities are Illegal Under U.S. Federal Laws**

**The concepts of “medical cannabis” and “retail cannabis” do not exist under U.S. federal law. The Federal Controlled Substances Act classifies “marijuana” as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. As such, cannabis-related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. Strict compliance with state laws with respect to cannabis will neither absolve the Issuer of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against the Issuer. Any such proceedings brought against the Issuer may adversely affect the Issuer’s operations and financial performance.**

**COVID-19**

**The Issuer may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to COVID-19. An outbreak of infectious disease, a pandemic, or a similar public health threat, such as the recent outbreak of COVID-19, or a fear of any of the foregoing, could adversely impact the Issuer by causing operating, manufacturing, supply chain, and project development delays and disruptions, labor shortages, travel, and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how the Issuer may be affected if such a pandemic persists for an extended period of time, including as a result of the waiver of regulatory requirements or the implementation of emergency regulations to which the Issuer is subject. Although the Issuer has been deemed essential and/or has been permitted to continue operating its facilities in the states in which it operates during the pendency of the COVID-19 pandemic, there is no assurance that the Issuer’s operations will continue to be deemed essential and/or will continue to be permitted to operate. The Issuer may incur expenses or delays relating to such events outside of its control, which could have a material adverse impact on its business, operating results, financial condition, and the trading price of the Issuer’s Common Shares.**

* **Certificate Of Compliance:**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is following the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **December 7, 2020**

**Eric Offenberger**Name of Director or Senior Officer

Text, letter

Description automatically generated

**Chief Executive Officer**   
Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***  Name of Issuer Vext Science, Inc. | For Month End  November, 2020 | Date of Report  YY/MM/DD  20/12/07 |
| Issuer Address  2250 – 1055 West Hastings Street | | |
| City/Province/Postal Code  Vancouver, British Columbia, V6E 2E9 | Issuer Fax No.  (778) 329-9361 | Issuer Telephone No.  (604) 688-9588 |
| Contact Name  Eric J. Offenberger | Contact Position  CEO/COO | Contact Telephone No.  (713) 725-4663 |
| Contact Email Address  [Eric@VextScience.com](mailto:Eric@VextScience.com) | Web Site Address  [www.VextScience.com](http://www.VextScience.com) | |